MSB 0.45% $1.10 mesoblast limited

Cell Therapy News/Articles, page-6191

  1. 309 Posts.
    lightbulb Created with Sketch. 103

    https://www.forbes.com/sites/alexknapp/2020/08/27/the-inside-story-of-biotechs-barnum-and-his-covid-cures/#1556de62208a

    Please check this link you will find this as below...

    The third weapon NantKwest and ImmunityBio are developing to combat Covid-19 involves the use of mesenchymal stem cells, which are derived from bone marrow. This type of stem cell has been investigated over the past decade for diseases—like Covid-19—that can cause the body’s immune system to go into overdrive and attack itself. This treatment would be for the most severely sick Covid-19 patients, who are experiencing a “cytokine storm,” in which the immune system overreacts. Small-scale studies have suggested this might be an effective treatment, and several companies, including Melbourne, Australia–based Mesoblast, are already in late-stage clinical trials for severe Covid-19 patients. Soon-Shiong’s companies are working with hospitals to recruit patients for human trials.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.10
Change
-0.005(0.45%)
Mkt cap ! $1.250B
Open High Low Value Volume
$1.08 $1.11 $1.08 $1.241M 1.145M

Buyers (Bids)

No. Vol. Price($)
16 182117 $1.10
 

Sellers (Offers)

Price($) Vol. No.
$1.10 25455 12
View Market Depth
Last trade - 11.34am 19/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.